The FDA has advised consumers not to use albuterol sulfate inhalation solution, 0.083%, and ipratropium bromide inhalation solutions, 0.02%, unit-dose vials, purchased after September 8, 2009 and ...

The Food and Drug Administration has advised consumers not to use certain respiratory medications purchased after Sept. 8, 2009 and manufactured by Dey L.P., a subsidiary of Mylan Inc., because the ...

Ipratropium Bromide (Ipravent Respirator Solution) is a bronchodilator, opens the air passages to the lungs, making it easier to breathe. It is used - on a regular schedule - to prevent bronchospam ...

Ipratropium bromide 0.5 mg/3 mL (0.017%), albuterol (as sulfate) 2.5 mg/3 mL (0.083%); soln for inh. Not for primary treatment of acute attack. Avoid excessive use. Discontinue if paradoxical ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the ... · ACCESS Newswire · Amphastar Pharmaceuticals, Inc. Amphastar ...

Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...

Review the side-effects of Ipratropium Bromide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...

Background: Studies have suggested an increased risk of cardiovascular morbidity and mortality associated with the use of ipratropium bromide. We sought to examine the association between ipratropium ...

Mumbai, July 4 -- Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc. The solution is indicated for the symptomatic relief of ...

Overview: Nasal ipratropium is used to help reduce symptoms of a runny nose. It works by reducing the amount of liquid and mucus made in your nose. Common side effects can include dryness of the nose, ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...